Ozempic used to assist remedy arthritis ache: Report
Fox Information medical contributor Dr. Marc Siegel joined ‘Fox & Mates’ to debate his tackle Ozempic getting used to remedy arthritis ache and why some docs are warning some drugs can have an effect on warmth sensitivity.
- Kind 2 diabetes sufferers on GLP-1 therapies, comparable to Ozempic, have a decrease danger of 10 obesity-related cancers in comparison with these on insulin and different medication, in response to a brand new research.
- GLP-1 therapies for kind 2 diabetes have been in the marketplace for almost 20 years, enhancing blood sugar management and inducing weight reduction.
- Ozempic, accredited in 2017, was one of many first in its class.
Sufferers with kind 2 diabetes taking GLP-1 therapies, which embody Ozempic, have a decrease likelihood of growing 10 kinds of obesity-related cancers than these taking insulin and different diabetes medication, in response to a research printed on Friday.
GLP-1 therapies for kind 2 diabetes have been in the marketplace for almost 20 years. The newer era – comparable to Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro – are far simpler at controlling blood sugar ranges and inducing weight reduction. Ozempic was the primary of the newer era within the class to be accredited, in 2017.
Within the research printed on Friday in medical journal JAMA Community Open, researchers examined the medical data of 1.6 million sufferers with kind 2 diabetes who had no prior historical past of 13 kinds of obesity-related cancers together with gallbladder most cancers and kidney most cancers.
OZEMPIC AND WEGOVY COULD DOUBLE AS KIDNEY DISEASE TREATMENT, STUDY SUGGESTS
The research didn’t specify which GLP-1 medicines the sufferers took, however the data have been for sufferers on these medicines or insulin or the diabetes drug metformin between March 2005 and November 2018. Ozempic was solely accredited by the U.S. Food and Drug Administration in December 2017.
Ozempic treatment bins are pictured in a pharmacy. Sufferers with kind 2 diabetes taking GLP-1 therapies, which embody Ozempic, have a decrease likelihood of growing 10 kinds of obesity-related cancers than these taking insulin and different diabetes medication, in response to a research printed on Friday. (SEBASTIEN BOZON/AFP by way of Getty Pictures)
The research discovered that the sufferers handled with a GLP-1 remedy as an alternative of insulin “had a major danger discount” in 10 of these cancers.
The findings are “preliminary proof of the potential profit” of GLP-1 medication for most cancers prevention in high-risk inhabitants, the researchers concluded. Additionally they mentioned that research of the newer era of those medicines for his or her most cancers preventative results are warranted.
The authors of the research didn’t report having acquired funds from drugmakers who market these medicines.
CLICK HERE TO GET THE FOX NEWS APP
The variations of those medicines which can be accredited to deal with weight problems, and have been proven to assist sufferers lose as a lot as 20% of their weight on common, have exploded in reputation, resulting in file earnings for Novo and Lilly.
Lilly’s Mounjaro and weight-loss remedy Zepbound, in addition to Novo’s rival medicines Ozempic and Wegovy are already being studied to see whether or not they can enhance well being in lots of different methods, starting from alcohol habit to sleep apnea.
In March, the U.S. Food and Drug Administration accredited Wegovy for decreasing the danger of stroke and coronary heart assault in chubby or overweight adults who should not have diabetes.
Discussion about this post